

**RECEIVED  
CENTRAL FAX CENTER**

**Restricted  
Confidential  
Limited access**

**NOV 12 2008**



Patent Department - RY 60-30  
Merck & Co., Inc.  
P.O. Box 2000  
Rahway, NJ 07065

**FACSIMILE COVER SHEET**

**Date: November 11, 2008**

**Please deliver the following message to:**

**Commissioner for Patents**

**Fax Number:** (571) 273-8300  
**Phone Number:** (571) 272-0688

**Examiner's Name:** Patricia L. Morris  
**Group number:** 1625  
**Phone number:** (571)272-0688

**This message is from:**

**Name:** J. Eric Thies  
**Fax number:** (732) 594-2250  
**Phone number:** (732) 594-3904

**RE:** **USSN:** 10/552,107  
**Filing Date:** October 3, 2005  
**Applicants' Ref.:** Case MS0038YP  
**For:** 4- RING IMIDAZOLE DERIVATIVES AS MODULATORS OF  
METABOTROPIC GLUTAMATE RECEPTOR-5

**NUMBER OF PAGES BEING TRANSMITTED (INCLUDING COVER): 9**

**IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL (732) 594-1251**


**CERTIFICATION OF FACSIMILE TRANSMISSION**

I hereby certify that this paper is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below

*Type or print name of person signing certification*

Christine Dona

*Signature*



*Date* November 11, 2008

2/9  
**RECEIVED**  
**CENTRAL FAX CENTER**  
**NOV 12 2008**

**Patent**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Nicholas D. P. Cosford et al.

Serial No. : 10/552,107

Case No.: MS0038YP

Art Unit:

1625

Filed : October 3, 2005

Examiner:

Patricia L. Morris

For : 4-RING IMIDAZOLE DERIVATIVES AS  
MODULATORS OF METABOTROPIC  
GLUTAMATE RECEPTOR-5

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**AMENDMENT UNDER 37 C.F.R. §1.111**

Sir:

In response to the Official action of August 11, 2008 for which a reply is due by November 11, 2008, or the next business day thereafter, the Applicants respectfully request reconsideration of the application in view of the following amendments and remarks. Any additional fees associated with this Response may be charged to Merck Deposit Account No. 13-2755.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this response. **Remarks** begin on page 8 of this response.